John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Carcinoid heart disease: pathophysiology, clinical features, biology, screening, prognosis and treatment Volume 23, supplement 2, Octobre 2016

Figures

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5

Tables

Authors
1 Hospices Civils de Lyon, Groupement Hospitalier Centre, Institut du Cancer, service d’oncologie médicale, Pavillon E, 5, place d’Arsonval, 69437 Lyon cedex 03, France
2 Hospices civils de Lyon, Groupement hospitalier Est, Hôpital cardiologique Louis Pradel, service de cardiologie, exploration fonctionnelle cardiovasculaire, Avenue doyen Lépine, 69500 Bron, France
3 Centre de Recherche en Cancérologie de Lyon (CRCL), Unité INSERM UMR 1052 CNRS UMR 5286 - Equipe 1, 69008 Lyon, France
* Tirés à part

Carcinoid heart disease is a rare form ofheart disease, occurring in over 50% of the patients with carcinoid syndrome.Pathophysiology remains unclearbut serotonin may play a major role. Cardiac symptoms secondary to severe dysfunction of tricuspid and pulmonary valve are often delayed and non specific: fatigability, dyspnea. Development of a carcinoid heart disease is associated with an increased morbidity and mortality. In patients with severe cardiac involvement, symptoms of right ventricular failure and well-controlled carcinoid syndrome, cardiac surgery (valve replacement) remains the only treatment that can improve both symptoms and survival, despite a high morbi-mortality. A standardized routine screening, monitoring and early management by specialized teams including cardiologists, anesthesiologists and surgeons is the only way to improve our knowledge and the prognosis of these patients.